1346697-39-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-bromo-4-cyclopropylpyrimidine is utilized as a building block for the synthesis of various pharmaceutical compounds, contributing to the development of new drugs.
Used in Antifungal and Antibacterial Applications:
5-bromo-4-cyclopropylpyrimidine has demonstrated potential as an antifungal and antibacterial agent in several studies, making it a promising candidate for the treatment of infections caused by fungi and bacteria.
Used in the Preparation of Kinase Inhibitors:
5-bromo-4-cyclopropylpyrimidine is employed in the synthesis of potential kinase inhibitors, which are important for the development of targeted therapies in the treatment of various diseases, including cancer.
Used in the Synthesis of Biologically Active Molecules:
As an important intermediate, 5-bromo-4-cyclopropylpyrimidine is used in the preparation of other bioactive compounds, enhancing the discovery and development of novel therapeutic agents.

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 23719-80-4 cyclopropylmagnesium bromide 

Downstream Products

• 1428880-27-6 7-(4-cyclopropylpyrimidin-5-yl)-3-(5-fluoro-2-methoxyphenyl)benzo[d]isoxazole 
• 1428880-87-8 7-(4-cyclopropylpyrimidin-5-yl)-3-(4-fluorophenyl)thieno[3,2-b]pyridine 
• 1428879-99-5 7-(4-cyclopropylpyrimidin-5-yl)-3-(4-fluorophenyl)benzo[d]isoxazole 
• 1428882-14-7 4-cyclopropylpyrimidin-5-ylboronic acid 
• 1428880-36-7 7-(4-cyclopropylpyrimidin-5-yl)-3-(4-fluoro-2-methoxyphenyl)benzo[d]isoxazole 

Relevant academic research and scientific papers

SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES

Provided herein are pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS

Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.

AZAINDAZOLE COMPOUNDS

Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.